Skip to navigation Skip to content

Chronic rhinosinusitis with nasal polyps (CRSwNP) in Pharmaceutical Benefits Scheme (PBS) 012-23031433

Expand/Collapse all sectionsExpand all


CRSwNP restriction and item codes

Do not share this attachment externally. See Freedom of Information - Information Publication Scheme.

\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.pngPBS CRSwNP restriction and item codes

Contact details

PBS Complex Drugs Programs

Forms

Chronic rhinosinusitis with nasal polyps - mepolizumab - initial authority application form (PB348)

Services Australia website

Chronic rhinosinusitis with nasal polyps

External websites

PBS schedule for Chronic rhinosinusitis with nasal polyps

FAQs from Service Officers

Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.

Item

Description

1

When the prescriber writes the eosinophils as 0.3, how is this entered in OPA?

The eosinophil count is entered in OPA as 300. Prescribers may use different units to those written in the restriction. Other examples:

  • 1.1 is entered as 1100, and
  • 0.15 is entered as 150

2

If the prescriber provides three baseline scores (bilateral endoscopic nasal polyp score, nasal obstruction visual analogue (VAS) score and overall symptom VAS score), should all three be entered in OPA?

Only the scores that meet the PBS requirements, as indicated on the form and the OPA question, should be entered.

The restriction only requires a minimum of two qualifying scores. If a score is entered that is not meeting, OPA will reject the application.